What is Biohaven's stock issuance proceeds?

Biohaven (BHVN) reported stock issuance proceeds of $178.88M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Biohaven BHVN Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Xenon PharmaceuticalsXENE

$5.49M+377%

Rapport Therapeutics, Inc.RAPP

$809K+13,383%

Vir Biotechnology, Inc.VIR

$162.35M—

uniQureQURE

$550K+246%

Roivant SciencesROIV

-$217.17M—

Protagonist TherapeuticsPTGX

$23.37M+96.1%

Other financials

Income statement

See full

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

See full

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

See full

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation

See full

Market cap$2.25B-48.1%

Returns & leverage

See full

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Biohaven's stock issuance proceeds?: Biohaven (BHVN) reported stock issuance proceeds of $178.88M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.